PURPOSE: C-peptide, a hormone secreted by the pancreas, is a marker for insulin production and hyperinsulinemia. Epidemiological studies have suggested an association between circulating C-peptide level and colorectal neoplasia risk; however, the results were not always consistent. Herein, we conducted a systematic review and meta-analysis study to evaluate the association between circulating C-peptide level and the colorectal neoplasia risk. METHODS: The PubMed database was searched for the eligibility studies updated to May 2013, which prospectively evaluated the association between circulating C-peptide level and colorectal neoplasia risk. The summary estimates and 95 % confidential intervals (95 % CIs) for those with the highest quantile C-peptide level in contrast to the lowest quantile were estimated with the random-effects model. Heterogeneity between the studies was assessed with the Q test and the I (2) statistic. Potential publication bias was evaluated with the Egger's test. RESULTS: We identified 9 nested case-control studies that have recruited a total of 3,109 cases and 4,285 controls met the criteria. From the meta-analysis, we found that subjects with high circulating C-peptide were associated with a 37 % increased colorectal neoplasia risk [pooled odds ratios (OR) 1.37, 95 % CI 1.09-1.72] under the random-effects model. In the stratification studies, we found the association was more prominent in the men (pooled OR 2.34, 95 % CI 1.36-4.04) compared to women (pooled OR 1.41, 95 % CI 0.89-2.25). Significant association between circulating C-peptide level and colon cancer risk was found (pooled OR 1.72, 95 % CI 1.26-2.36), but not for rectal cancer (pooled OR 1.14, 95 % CI 0.75-1.73). No significant publication bias was found for any meta-analysis study. CONCLUSION: In conclusion, the results of the meta-analysis studies suggested that higher circulating C-peptide could be a predictive factor for higher colorectal neoplasia susceptibility.
PURPOSE:C-peptide, a hormone secreted by the pancreas, is a marker for insulin production and hyperinsulinemia. Epidemiological studies have suggested an association between circulating C-peptide level and colorectal neoplasia risk; however, the results were not always consistent. Herein, we conducted a systematic review and meta-analysis study to evaluate the association between circulating C-peptide level and the colorectal neoplasia risk. METHODS: The PubMed database was searched for the eligibility studies updated to May 2013, which prospectively evaluated the association between circulating C-peptide level and colorectal neoplasia risk. The summary estimates and 95 % confidential intervals (95 % CIs) for those with the highest quantile C-peptide level in contrast to the lowest quantile were estimated with the random-effects model. Heterogeneity between the studies was assessed with the Q test and the I (2) statistic. Potential publication bias was evaluated with the Egger's test. RESULTS: We identified 9 nested case-control studies that have recruited a total of 3,109 cases and 4,285 controls met the criteria. From the meta-analysis, we found that subjects with high circulating C-peptide were associated with a 37 % increased colorectal neoplasia risk [pooled odds ratios (OR) 1.37, 95 % CI 1.09-1.72] under the random-effects model. In the stratification studies, we found the association was more prominent in the men (pooled OR 2.34, 95 % CI 1.36-4.04) compared to women (pooled OR 1.41, 95 % CI 0.89-2.25). Significant association between circulating C-peptide level and colon cancer risk was found (pooled OR 1.72, 95 % CI 1.26-2.36), but not for rectal cancer (pooled OR 1.14, 95 % CI 0.75-1.73). No significant publication bias was found for any meta-analysis study. CONCLUSION: In conclusion, the results of the meta-analysis studies suggested that higher circulating C-peptide could be a predictive factor for higher colorectal neoplasia susceptibility.
Authors: Keming Yang; Michele R Forman; Patrick O Monahan; Brett H Graham; Andrew T Chan; Xuehong Zhang; Immaculata De Vivo; Edward L Giovannucci; Fred K Tabung; Hongmei Nan Journal: J Nutr Date: 2020-08-01 Impact factor: 4.798
Authors: Dong Hoon Lee; Leandro Fórnias Machado de Rezende; José Eluf-Neto; Kana Wu; Fred K Tabung; Edward L Giovannucci Journal: Int J Cancer Date: 2019-01-24 Impact factor: 7.396
Authors: Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254
Authors: Fred K Tabung; Weike Wang; Teresa T Fung; Frank B Hu; Stephanie A Smith-Warner; Jorge E Chavarro; Charles S Fuchs; Walter C Willett; Edward L Giovannucci Journal: Br J Nutr Date: 2016-11-08 Impact factor: 3.718
Authors: Wenjie Ma; Mingyang Song; Andrew T Chan; Edward L Giovannucci; Xuehong Zhang; Ane Sørlie Kværner; Jennifer Prescott Journal: Cancer Prev Res (Phila) Date: 2018-07-10
Authors: Y Yue; J Hur; Y Cao; F K Tabung; M Wang; K Wu; M Song; X Zhang; Y Liu; J A Meyerhardt; K Ng; S A Smith-Warner; W C Willett; E Giovannucci Journal: Ann Oncol Date: 2021-04-01 Impact factor: 51.769
Authors: Lauren C Houghton; Michael N Pollak; Yuzhen Tao; Ying Gang Tu; Amanda Black; Gary Bradwin; Robert N Hoover; Rebecca Troisi Journal: Biomark Cancer Date: 2015-06-08
Authors: Neil Murphy; Mingyang Song; Nikos Papadimitriou; Robert Carreras-Torres; Claudia Langenberg; Richard M Martin; Konstantinos K Tsilidis; Inês Barroso; Ji Chen; Timothy M Frayling; Caroline J Bull; Emma E Vincent; Michelle Cotterchio; Stephen B Gruber; Rish K Pai; Polly A Newcomb; Aurora Perez-Cornago; Franzel J B van Duijnhoven; Bethany Van Guelpen; Pavel Vodicka; Alicja Wolk; Anna H Wu; Ulrike Peters; Andrew T Chan; Marc J Gunter Journal: J Natl Cancer Inst Date: 2022-05-09 Impact factor: 11.816